CFL1 and hepatocellular carcinoma: Recently, nanoparticles-mediated co-delivery of cofilin 1 (CFL1) silencing with sorafenib, a chemotherapeutic agent, showed elevated inhibitory properties for HCC tumor growth without exhibiting significant toxicity (Li S. et al., 2023).